Renchen Biotechnology is a non-invasive prenatal early screening technology and product developer. The company achieves high-efficiency and high-precision capture and separation of human trophoblast stem cells, and realizes high-reliability non-invasive prenatal early screening. At present, the company’s pipeline mainly includes: early screening and diagnosis of premature birth, preeclampsia, non-invasive prenatal early screening of fetal malformation; and a series of backup pipelines such as TORCH detection and many C-end consumer products such as pregnancy self-test kits. Renchen Biotech recently completed an angel round of financing. Zijingang Capital completed this financing, which will be used for the R&D registration and team building of pipelines such as preterm birth and preeclampsia screening and diagnosis.
This article is transferred from: https://www.itjuzi.com/investevent/13752617
This site is only for collection, and the copyright belongs to the original author.